Now with significant technological advances and progress in eCBome research, it may be feasible to produce ligands with opposing activation profiles of CB1R and CB2R with high degree of selectivity in obesity, neuropsychiatric and neurodegenerative disorders. The gene discussed is CNR1; the disease is Obesity.